-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

JOINT SESSION: Emerging Therapeutic Strategies Targeting Epigenetic, Transcriptomic, and Metabolic Mechanisms

PhD Trainee
Sponsor: Scientific Committee on Epigenetics and Genomics||Scientific Committee on Myeloid Neoplasia
Program: Scientific Program
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Genomics, Biological Processes, Metabolic Disorders
Sunday, December 8, 2024: 9:30 AM-11:05 AM
Room 24 (San Diego Convention Center)

Description:
Recent developments in therapeutic targeting of various mechanisms of epigenetic, transcriptomic, and metabolic vulnerabilities in cancer utilize novel technologies and may provide future breakthroughs. Given the extensive amount of knowledge derived from high throughput methodologies in the last decade, rational targeting is now possible, with sophisticated mechanistic studies to study the effects of targeting. This session will focus on novel research aimed at identifying and targeting these molecules, including novel targeting approaches such as heterobifunctional molecules and others.

Dr. Crabtree will discuss a new approach to make cancer therapeutics by rewiring cancer drivers to activate po pathways of apoptosis) (Gourisankar et al., Nature 2023, PMID: 37495688 ; Sarott et al., Science 2024, PMID: 39361741).  The approach uses chemically induced proximity (CIP) and to kill the cancer cell with its driver. The molecules, called TCIPs (Transcriptional/Epigenetic Chemical Inducers of Proximity) rapidly reverse epigenetic repression of cell death genes and eliminates lymphoma in several CDX and PDX mouse models.

Dr. Cravatt will discuss novel small molecules that target RNA binding proteins.  Traditionally considered undruggable, RNA binding proteins may be targetable through the use of chemo proteomic approaches to identify ligandable sites.  Dr. Cravatt’s group has successfully employed this strategy to develop chemical probes that can engage cysteine residues in RNA binding proteins and regulate their activity in gene regulation.

Dr. Uckelmann will discuss novel inhibitors of transcriptional mechanisms. Previous work of Dr. Uckelmann has focused on elucidating the role of mutant NPM1 (NPM1c) in regulating oncogenic gene expression in acute myeloid leukemia (AML) cells. Her work showed that the chromatin specific function of the NPM1c oncoprotein can be targeted by Menin-MLL inhibitors which are currently in clinical trials for treatment of NPM1c leukemia. In her talk she will discuss emerging developments in our mechanistic understanding and therapeutic targeting of epigenetic regulators in AML.

Dr. Jones will discuss targeting metabolic dependencies in leukemia. Acute myeloid leukemia (AML) cells and leukemia stem cells (LSCs) have unique metabolic properties that can be leveraged to develop new therapeutic strategies. In this presentation, she will discuss complementary approaches to target metabolism in AML and LSCs.  These approaches include mechanisms to target energy metabolism, metabolite regulated protein synthesis and post-translational modifications, as well as the potential for using metabolite abundance to predict resistance to therapy.

Co-chairs:
Dinesh S. Rao, MD, PhD, University of California Los Angeles and Daniel Starczynowski, PhD, Cincinnati Children's Hospital
Disclosures:
Rao: International Myeloma Foundation: Consultancy; AbbVie, Inc: Consultancy, Speakers Bureau. Starczynowski: Curis: Honoraria; Tolero: Research Funding; Kymera: Consultancy; Kurome: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Treeline Biosciences: Research Funding.
Recent developments in therapeutic targeting of various mechanisms of epigenetic, transcriptomic, and metabolic vulnerabilities in cancer utilize novel technologies and may provide future breakthroughs. Given the extensive amount of knowledge derived from high throughput methodologies in the last decade, rational targeting is now possible, with sophisticated mechanistic studies to study the effects of targeting. This session will focus on novel research aimed at identifying and targeting these molecules, including novel targeting approaches such as heterobifunctional molecules and others.

Dr. Crabtree will discuss a new approach to make cancer therapeutics by rewiring cancer drivers to activate po pathways of apoptosis) (Gourisankar et al., Nature 2023, PMID: 37495688 ; Sarott et al., Science 2024, PMID: 39361741).  The approach uses chemically induced proximity (CIP) and to kill the cancer cell with its driver. The molecules, called TCIPs (Transcriptional/Epigenetic Chemical Inducers of Proximity) rapidly reverse epigenetic repression of cell death genes and eliminates lymphoma in several CDX and PDX mouse models.

Dr. Cravatt will discuss novel small molecules that target RNA binding proteins.  Traditionally considered undruggable, RNA binding proteins may be targetable through the use of chemo proteomic approaches to identify ligandable sites.  Dr. Cravatt’s group has successfully employed this strategy to develop chemical probes that can engage cysteine residues in RNA binding proteins and regulate their activity in gene regulation.

Dr. Uckelmann will discuss novel inhibitors of transcriptional mechanisms. Previous work of Dr. Uckelmann has focused on elucidating the role of mutant NPM1 (NPM1c) in regulating oncogenic gene expression in acute myeloid leukemia (AML) cells. Her work showed that the chromatin specific function of the NPM1c oncoprotein can be targeted by Menin-MLL inhibitors which are currently in clinical trials for treatment of NPM1c leukemia. In her talk she will discuss emerging developments in our mechanistic understanding and therapeutic targeting of epigenetic regulators in AML.

Dr. Jones will discuss targeting metabolic dependencies in leukemia. Acute myeloid leukemia (AML) cells and leukemia stem cells (LSCs) have unique metabolic properties that can be leveraged to develop new therapeutic strategies. In this presentation, she will discuss complementary approaches to target metabolism in AML and LSCs.  These approaches include mechanisms to target energy metabolism, metabolite regulated protein synthesis and post-translational modifications, as well as the potential for using metabolite abundance to predict resistance to therapy.

Hannah J Uckelmann, PhD

Frankfurt Cancer Institute, Frankfurt, Germany

Gerald R. Crabtree, MD

Stanford University, Stanford, CA

Benjamin Cravatt, PhD

The Scripps Research Institute, San Diego, CA

Courtney Jones, PhD

Cincinnati Children's Hospital, Cincinnati, OH

See more of: Scientific Program